TO THE EDITOR:

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma

Alexis Cuffel,1,2 Vincent Allain,1,2 Lionel Faire,2-4 Roberta Di Blasi,5 Florence Morin,1,2 Laetitia Vercellino,6 Mathieu F. Chevalier,2 Aude Desnoyer,3,4 Romain de Jorna,7 Isabelle Madelaine,7 Nathalie Parquet,8 Anne C. Brignier,8 Catherine Thieblemont,5 Jerome Larghero,2-4 Sophie Caillat-Zucman,1,2 and Miryam Mebarki2-4

1Laboratoire d’Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France; 2Pathophysiology and Immunotherapy, Institut National de la Santé et de la Recherche Médicale, UMR978 Human Immunology, Paris, France; 3Unité de Thérapie Cellulaire, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France; 4CIC de Biothérapies CBT50, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale, Paris, France; 5Service d’Hématologue, and 6Département de Médecine Nucléaire, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France; and 7Pharmacie à Usage Intérieur and 8Unité d’Apheresèse Thérapeutique, Hôpital Saint-Louis, AP-HP, Paris, France

CD19-directed chimeric antigen receptor (CAR) T cells have greatly improved the prognosis of relapsed/refractory large B-cell lymphoma (LBCL), yet treatment failure occurs in > 50% of patients, usually in the first 3 months after CAR T-cell infusion.1-3 Apart from patient status and tumor burden,4 early factors capable of predicting a durable response would be crucial in better selecting patients at the time of decision to treat (ie, before the manufacture of CAR T cells) to avoid a costly and potentially life-threatening treatment when it has little chance of clinical benefits.

The quality of apheresed T cells, which represent the starting material for CAR T-cell manufacture, has emerged as a strong determinant of antitumor response in patients with B-cell malignancies. Early lineage phenotypes are essential to T-cell fitness but are altered by cumulative chemotherapy cycles.5,6 Naïve and central memory enriched T cells generated CAR products that retained replicative potential and were associated with complete and sustained remission in various clinical trials.7-11 Notably, in patients with LBCL treated with axicabtagene ciloleucel (axi-cel; CD19-CD28 CAR T), a higher proportion of naïve/stem cell memory T cells in the apheresis product was associated with rapid expansion during CAR T-cell manufacturing and a durable response.12 However, data are missing in the real-life setting, from which patients are less often selected. Here, we investigated whether intrinsic characteristics of apheresed T lymphocytes influence the clinical response to tisagenlecleucel (tisa-cel; CD19-4.1BB CAR T) in real-life patients with LBCL.

We studied 30 consecutive patients with aggressive diffuse LBCL or transformed follicular lymphoma who received commercial tisa-cel between April 2019 and March 2020 in our center. All patients were alive beyond 28 days and evaluable for response. Response assessment was performed at 1, 3, 6, and 12 months per institutional practice and based on Lugano criteria.13 Parameters of immune monitoring were routinely determined as a standard of care. The number of total and CAR T cells in the final product was obtained from the manufacturer’s release certificate. The study was performed under institutional review board–approved protocols, and all patients signed informed consent.

Cryopreserved mononuclear cells from the apheresis product were used retrospectively for this study. Cells were stained with combination of antibodies, allowing differentiation of naïve/stem cell memory (TNaive; CD45RO−CD27+), central memory (TCM; CD45RO−CD27+), effector memory (TEM; CD45RO+CD27−), and effector (TEFF; CD45RO−CD27−) populations among CD4 and CD8 subsets (supplemental Table 1). We previously verified in 9 patients the perfect correlation between T-cell phenotypes in the cryopreserved apheresis product and fresh peripheral blood collected on the...
same day (supplemental Figure 1). For proliferation assays, carboxyfluorescein succinimidyl ester (CFSE)–labeled mononuclear cells were cultured with Dynabeads human T-activator CD3/CD28 (1:1 ratio) for 5 days, after which T-cell proliferation was quantified according to CFSE dilution. Samples were acquired using Attune NxT flow cytometer (Thermo Fisher) and analyzed in FlowJo. T-cell phenotypes were validated using unsupervised analysis with the FlowSOM clustering and visualization algorithm (supplemental Figure 2).

Statistics were performed using Prism v9 (GraphPad). Statistical tests used are indicated in figure legends. P values < 0.05 were considered significant.

Figure 1. Intrinsic characteristics of apheresed T cells and quality of the CAR T-cell product. (A) Representative staining of naïve/stem cell memory (T<sub>N/SCM</sub>; CD45RO<sup>−</sup>CD27<sup>+</sup>), central memory (T<sub>CM</sub>; CD45RO<sup>−</sup>CD27<sup>+</sup>), effector memory (T<sub>EM</sub>; CD45RO<sup>−</sup>CD27<sup>−</sup>), and effector (T<sub>EFF</sub>; CD45RO<sup>−</sup>CD27<sup>−</sup>) CD8 and CD4 subsets in apheresed T lymphocytes. (B) Distribution of T<sub>N/SCM</sub>, T<sub>CM</sub>, T<sub>EM</sub>, and T<sub>EFF</sub> CD8 and CD4 T cells in apheresed T lymphocytes from 30 patients treated with tisa-cel. Bars represent the median. (C) Correlation between the naïve/stem cell memory phenotype and in vitro proliferative capacity (proportion of CFSE<sup>low</sup> cells) of apheresed CD8 (left panel) and CD4 (right panel) T cells. (D) The CD4/CD8 T-cell ratio in the final product correlates with the ratio of CD4 T<sub>N/SCM</sub> to CD8 T<sub>N/SCM</sub> cells in the apheresis (left) and the ratio of CFSE<sup>low</sup> CD4 to CD8 T cells (right). Pearson correlation test. p coefficient (R) and P values are indicated.
Characteristics of the patients are shown in supplemental Table 2. The distribution of naïve, memory, and effector CD4 and CD8 subsets among apheresed T lymphocytes was highly heterogeneous among patients (Figure 1A-B). The phenotype of apheresed T cells had a strong impact on their functional fitness, as shown by the correlation between the proportion of naïve/stem cell memory cells and the ability of CD4 and CD8 T cells to proliferate in vitro (Figure 1C). It also impacted the relative expansion of CD4 and CD8 T cells during the CAR T-cell manufacturing process. Thus, the CD4/CD8 ratio among total T cells (or CAR⁺ T cells) in the final product was significantly related to the ratio between CD4 T_NSCM and CD8 T_NSCM in the apheresis ($R = 0.50$; $P < .01$) and proliferative potential of CD4 relative to CD8 T cells ($R = 0.65$; $P < .01$) (Figure 1D; supplemental Figure 3). These data indicate that the proportions of CD4 and CD8 T_NSCM cells in the starting material are critical for the quality of the CAR T-cell product.

We then determined whether apheresed T-cell characteristics correlated with clinical outcome. Objective responses (partial or complete) around day 30 were observed in 13 out of 30 patients (43.3%). CD4/CD8 ratio in starting material had no impact on clinical response (not shown). However, early responders had a higher proportion of CD8 T_NSCM than nonresponders (mean 17.8% vs 9.0%; $P = .02$) while CD4 T_NSCM were not different (Figure 2A).
At 3 months, 7 patients showed a complete response, which was associated with a higher proportion of CD8 T N/SCM (mean 19.0% vs 11.0% in nonresponders; \( P = .02 \)) and a lower CD4 T N/SCM/CD8 T N/SCM ratio (mean 0.47 vs 0.73; \( P = .05 \)) (Figure 2B). Moreover, complete responders had CD8 T cells with higher in vitro proliferative potential than nonresponders (mean 46.4% vs 18.4%; \( P = .05 \)), while the opposite was observed for CD4 T cells (mean 31.7% vs 63.0%; \( P = .03 \)) (Figure 2C). These data indicate that stemness and replicative potential of CD8 T cells at the time of apheresis are beneficial for the early response to CAR T cells, while those of CD4 T cells appear to be deleterious.

One-year estimates of progression-free survival (PFS) and overall survival (OS) were 26.7% and 53.3%, respectively, for the entire cohort (supplemental Figure 4A). Notably, the PFS was 57.1% in patients with a high proportion of CD8 T N/SCM (>18.6%; ie, the 4th quartile) but only 21.7% for the others (\( P = .04 \)), while an opposite trend was observed for CD4 T N/SCM. Thus, a low ratio of CD4 T N/SCM/CD8 T N/SCM at apheresis was associated with higher PFS (Figure 2D). PFS was also associated positively with the in vitro proliferative potential of apheresed CD8 T cells but negatively with that of CD4 T cells (Figure 2E). Similar tendencies were observed in OS (supplemental Figure 4B-C). Finally, PFS tended to be higher in patients with a low CD4/CD8 ratio in the final product (among total T cells or CAR T cells) (supplemental Figure 4D).

We identified additional patient characteristics associated with early response (supplemental Table 3). Because our intent was to provide an early predictive marker to better aid in the decision whether to proceed with CAR T-cell manufacturing, we performed multivariate analysis, including only the parameters measured at the time of decision to treat. Higher International Prognostic Index and lower CD8 T N/SCM proportion were independently associated with lack of complete response at M3 (\( P = .009 \) and .05, respectively).

Altogether, these preliminary results on a small patient cohort show that the T N/SCM phenotype at the time of apheresis has a strong impact on the early and sustained response to tisca-cel in real life. Whether comparable results are observed in patients treated with axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2546-2554.

Weber, A.C., Caillat-Zucman, S.C.-Z., and M.M. conceived the work and wrote the manuscript; M.M., J.L., and S.C.-Z. supervised the work; A.C., S.C.-Z., and M.M. performed the experiments and/or analyzed the data; and all authors read and approved the final manuscript.

Conflicts-of-interest disclosure: C.T. received honoraria from Roche, Amgen, Janssen, Celgene, Gilead Science/Kite, and Beigene; reported a consulting/advisory role from Roche, Gilead Sciences, Janssen, Celgene, Novartis, and Beigene; and received research funding and travel and accommodations expenses from Roche and Novartis. J.L. received honoraria from Novartis, Kite/Gilead, BMS/Celgene, and Janssen. S.C.-Z. received honoraria from Novartis and Kite/Gilead. M.M. received honoraria from Novartis, Kite/Gilead, and Janssen. A.C.B. received support from Kite/Gilead for attending a meeting. R.d.J. received honoraria from Novartis and Kite/Gilead. The remaining authors declare no competing financial interests.

ORCID profiles: A.C., 0000-0003-4036-8558; R.D.B., 0000-0001-9001-573X; M.F.C., 0000-0002-5601-2217; A.D., 0000-0003-3534-2206; R.d.J., 0000-0003-4843-3123; S.C.-Z., 0000-0002-4535-3550; M.M., 0000-0003-5413-0483.

Correspondence: Sophie Caillat-Zucman, Laboratoire d’Immunologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; e-mail: sophie.caillat-zucman@aphp.fr.

References

1. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2546-2554.
2. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
3. Schuster SJ, Bishop MR, Tam CS, et al; JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.
4. Vercellino L, Di Blasi R, Kanoun S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4(22):5607-5615.
5. Singh N, Perazzelli J, Grupp SA, Barrett DM. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016;8(320):320ra3.
6. Das RK, Vernau L, Grupp SA, Barrett DM. Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers. Cancer Discov. 2019;9(4):492-499.
7. Xu Y, Zhang M, Ramos CA, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750-3759.
8. Sommermeyer D, Hudecek M, Kosaish PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500.
9. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563-571.
10. Chen GM, Chen C, Das RK, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11(9):2186-2199.
11. Singh N, Lee YG, Shestova O, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10(4):552-567.
12. Locke FL, Rossii JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4988-4911.
13. Cheson BD, Fisher RI, Barrington SF, et al; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-3068.